Our Commitment
Our Commitment to lmmunology Biosimilars
Manufactured the first etanercept biosimilar
Biogen’s joint venture was the first to develop a biosimilar of this advanced fusion protein.1
First to give HCPs an anti-TNF biosimilar choice1-3
Biogen was the first company in the EU to offer both subcutaneous options with a biosimilar etanercept and adalimumab, and an lV option with a biosimilar infliximab. With the launch of Tofidence™ (tocilizumab) we have broadened our immunology portfolio.
Help start a sustainable movement with biosimilars
We have a long history of supporting HCPs, patients and healthcare system sustainability within the immunology space4
TOFIDENCE is brought to you by one of the leading providers of anti-TNF biosimilars in Europe, since 20164
We generated an estimated €7.6 billion in savings for European healthcare systems from 2016 until the end of 20215
Serving more than
272,000 patients
within
30 countries
across
20 indications
with our immunology anti-TNF portfolio and ophthalmology with ranibizumab4,6,7
More Access, More Savings, More Choice
Biosimilars increase patient access, allowing patients to access treatments earlier and for longer7,8
Enabling earlier access and treatment with biologics can reduce long-term disease burden on patients8
Help start a movement for more patients
You also might be interested in:
Abbreviations: HCP, healthcare professional; IV, intravenous; RWE, real-world evidence; TNF, tumour necrosis factor.
